Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cypher Genomics, Illumina Enter Biomarker Agreement

Published: Saturday, July 26, 2014
Last Updated: Saturday, July 26, 2014
Bookmark and Share
Co-promotion agreement to facilitate genomic biomarker discovery.

Cypher Genomics, Inc. has announced a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials.

Cypher Genomics and Illumina will jointly offer pharmaceutical companies, through Illumina's sales force, a solution including Illumina's market leading sequencing technology, the NextBio platform for data analytics and storage, and Cypher Genomics' biomarker discovery service, called Coral™.

Cypher Genomics technology reduces the signal-to-noise in genomic information to uncover important biomarkers in sample sizes typical of early stage drug development studies.

"Cypher Genomics' biomarker discovery service is a perfect complement to Illumina's whole genome sequencing and our NextBio analytics platform," said Nick Naclerio, SVP Corporate Development and General Manager Enterprise Informatics of Illumina. "We look forward to working with Cypher Genomics to provide our mutual customers with the sequencing, data interpretation, and data mining they require for biomarker discovery with whole genome data."

"We founded Cypher Genomics to transform the practice of medicine through fast and accurate genome interpretation. Cypher Genomics' biomarker discovery service, Coral™, includes technology that has a proven track record of success with pharmaceutical companies to discover the genetic basis of response to drug therapy," states Ashley Van Zeeland, Ph.D., co-founder and chief executive officer of Cypher Genomics.

The benefits of biomarker discovery to deliver precision medicine is clear - better tools that can match therapies to patients not only improves clinical outcomes but also reduce clinical trial sizes, which can accelerate time to market for life-saving therapies.

Many desire to look beyond biomarker panels to the whole genome, but biomarker discovery based on whole genome data generally has not been feasible due to the lack of statistical power within the small sample sizes of early clinical studies.

Cypher's genomic analysis platform provides highly accurate genome annotations combined with advanced statistical techniques to enable biomarker discovery studies with sample sizes in the hundreds, reflecting the reality of many Phase 2 clinical trials.

Adam Simpson, president and chief operating officer of Cypher Genomics, added, "Working with Illumina to offer best-in-class sequencing and analysis to pharmaceutical companies enables acceleration of their personalized drug development efforts and will ultimately help deliver on the promise of precision medicine."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!